Short Report

You have full text access to this OnlineOpen article

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma

  1. Verena Voelter1,†,*,
  2. Annie-Claire Diserens2,
  3. Alexandre Moulin3,
  4. Georg Nagel4,
  5. Pu Yan5,
  6. Eugenia Migliavacca6,7,
  7. Donata Rimoldi8,
  8. Marie-France Hamou2,
  9. Bernd Kaina4,
  10. Serge Leyvraz1,
  11. Monika E. Hegi2,7,*

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23632

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1215–1218, 1 September 2008

Additional Information

How to Cite

Voelter, V., Diserens, A.-C., Moulin, A., Nagel, G., Yan, P., Migliavacca, E., Rimoldi, D., Hamou, M.-F., Kaina, B., Leyvraz, S. and Hegi, M. E. (2008), Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. Int. J. Cancer, 123: 1215–1218. doi: 10.1002/ijc.23632

Author Information

  1. 1

    Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

  2. 2

    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

  3. 3

    Hôpital Ophtalmique Jules Gonin, University of Lausanne, Lausanne, Switzerland

  4. 4

    Department of Toxicology, University of Mainz, Mainz, Germany

  5. 5

    Department of Pathology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

  6. 6

    Swiss Institute of Bioinformatics, Lausanne, Switzerland

  7. 7

    National Center of Competence in Research Molecular Oncology, ISREC, Epalinges, Switzerland

  8. 8

    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland

  1. †

    Fax: +41-21-314-0737

*Centre Pluridisciplinaire d'Oncologie, CePO, University of Lausanne Hospitals, CHUV, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 4 MAR 2008
  4. Manuscript Received: 1 DEC 2007

Funded by

  • Nélia and Amadeo Barletta Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (180K)

References

  • 1
    Scotto J,Fraumeni JF,Jr,Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976; 56: 489–91.
  • 2
    Hakulinen T,Teppo L,Saxen E. Cancer of the eye, a review of trends and differentials. World Health Stat Q 1978; 31: 143–58.
  • 3
    Diener-West M,Hawkins BS,Markowitz JA,Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110: 245–50.
  • 4
    Desjardins L,Dorval T,Lévy C,Cojean I,Schlienger P,Slamon R,Validire P,Asselain B. Etude randomisée de chimiothérapie adjuvante par le Déticène dans le mélanome choroïdien. Ophtalmologie 1998; 12: 168–73.
  • 5
    COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119: 670–6.
  • 6
    Leyvraz S,Spataro V,Bauer J,Pampallona S,Salmon R,Dorval T,Meuli R,Gillet M,Lejeune F,Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15: 2589–95.
  • 7
    Peters S,Voelter V,Zografos L,Pampallona S,Popescu R,Gillet M,Bosshard W,Fiorentini G,Lotem M,Weitzen R,Keilholz U,Humblet Y, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17: 578–83.
  • 8
    Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296–307.
  • 9
    Ochs K,Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000; 60: 5815–24.
  • 10
    Esteller M,Garcia-Foncillas J,Andion E,Goodman SN,Hidalgo OF,Vanaclocha V,Baylin SB,Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350–4.
  • 11
    Hegi ME,Diserens AC,Gorlia T,Hamou MF,de Tribolet N,Weller M,Kros JM,Hainfellner JA,Mason W,Mariani L,Bromberg JE,Hau P, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003.
  • 12
    Stupp R,Mason WP,van den Bent MJ,Weller M,Fisher B,Taphoorn MJ,Belanger K,Brandes AA,Marosi C,Bogdahn U,Curschmann J,Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96.
  • 13
    Marini A,Mirmohammadsadegh A,Nambiar S,Gustrau A,Ruzicka T,Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006; 126: 422–31.
  • 14
    Esteller M,Hamilton SR,Burger PC,Baylin SB,Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793–7.
  • 15
    Hoon DS. Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma? Nat Clin Pract Oncol 2004; 1: 74–5.
  • 16
    Kohonen-Corish MR,Cooper WA,Saab J,Thompson JF,Trent RJ,Millward MJ. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 2006; 126: 167–71.
  • 17
    Rastetter M,Schagdarsurengin U,Lahtz C,Fiedler E,Marsch W,Dammann R,Helmbold P. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 2007; 22: 1005–15.
  • 18
    Palmisano WA,Divine KK,Saccomanno G,Gilliland FD,Baylin SB,Herman JG,Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954–8.
  • 19
    Wiewrodt D,Nagel G,Dreimüller N,Hundsberger T,Perneczky A,Kaina B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer 2008; 122: 1391–9.
    Direct Link:
  • 20
    Isowa G,Ishizaki K,Sadamoto T,Tanaka K,Yamaoka Y,Ozawa K,Ikenaga M. O6-methylguanine-DNA methyltransferase activity in human liver tumors. Carcinogenesis 1991; 12: 1313–7.
  • 21
    Bedikian AY,Legha SS,Mavligit G,Carrasco CH,Khorana S,Plager C,Papadopoulos N,Benjamin RS. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76: 1665–70.
    Direct Link:
  • 22
    Middleton MR,Lee SM,Arance A,Wood M,Thatcher N,Margison GP. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000; 88: 469–73.
    Direct Link:
  • 23
    Spiro TP,Liu L,Majka S,Haaga J,Willson JK,Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001; 7: 2309–17.
  • 24
    Fornace AJ,Jr,Papathanasiou MA,Hollander MC,Yarosh DB. Expression of the O6-methylguanine-DNA methyltransferase gene MGMT in MER+ and MER− human tumor cells. Cancer Res 1990; 50: 7908–11.
  • 25
    Citron M,Graver M,Schoenhaus M,Chen S,Decker R,Kleynerman L,Kahn LB,White A,Fornace AJ,Jr,Yarosh D. Detection of messenger RNA from O6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 1992; 84: 337–40.
  • 26
    Rodriguez FJ,Thibodeau SN,Jenkins RB,Schowalter KV,Caron BL,O'Neill BP,James CD,Passe S,Slezak J,Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 2008; 16: 59–65.
  • 27
    Preusser M,Janzer R,Felsberg J,Reifenberger G,Hamou M-F,Diserens AC,Stupp R,Gorlia T,Marosi C,Heinzl H,Hainfellner J,Hegi M. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 10.1111/j.1750-3639.2008.00153.x.
View Full Article (HTML) Get PDF (180K)